Enzolytics Inc (OTCMKTS: ENZC) is red hot and moving northbound with power after the Texas-based biotech announced it entered into a non-binding term sheet with SPAC Sagaliam Acquisition Corp. (NASDAQ: SAGA) for the sale of Biogenysis and Virogentics in a transaction valued at $250 million. BGEN and VIRO will become wholly owned subsidiaries of Sagaliam, currently trading on NASDAQ, and will adopt SAGA Scientific Holdings Corp. as the corporate name. Sagaliam raised $116.5 million in its initial public offering on December 23, 2021, and currently has $10 million in the treasury and expects to raise additional capital through a private investment in public equities (“PIPE”). The anticipated capital raise will be used to fund the clinical trials of ITV-1, marketing of IPF Immune™, production of fully human monoclonal antibodies (mAbs) and continued advancement in its proprietary technology involving the application of Artificial Intelligence (AI) in therapeutic discoveries and production. The deal with be finalized by Mary 19, 2023. As many ENZC investors have pointed out, after spinning off Biogenysis and Virogentics into SAGA the only things left will be Clone 3 and Covid MABs. Meanwhile ENZC shareholders will own shares in a Nasdaq listed biotech which raised $116.5 million in its initial public offering on December 23, 2021, and currently has $10 million in the treasury and expects to raise additional capital through a private investment in public equities (“PIPE”) furthering its market disrupting therapeutics, ITV-1, IPF Immune™
ENZC was among the biggest reverse mergers of 2020/21 making a historic run up the charts that started off in the triple zeroes and ran for many months culminating in highs over $0.90 per share. ENZC Investors are looking for a move back to previous levels before May 19. Enzolytics has a massive following of investors and many more on the sidelines looking to jump in on any sustained upward movement. Enzolytics recently reporting results of Toxicology studies of ITV-1 confirmed it is non-toxic, a crucial step in getting the EME approved in Europ. Enzolytics is entering the markets of Rwanda, DR Congo, Botswana, and Kenya to start where there are 4 million HIV infected individuals. It is estimated that the hospitals will administer ITV-1 to 40,000 – 50,000 patients accounting for $45 million USD in sales in its first year. Immune™ has also been registered with the FDA for use in the U.S. under NDI reg. no. 1083. In tests, IPF Immune™ has demonstrated significant beneficial effects for various diseases by bolstering the immune system. ENZC recently launched the product to multiple retailers including Amazon and got NPI to be their distributor. Sales have been brisk as Immunity boosters continue to see record growth. ENZC is looking to make a mark on the North American dietary supplements market valued at over $50 Billion in 2020. We will be updating on ENZC and SAGA when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Enzolytics Inc (OTCMKTS: ENZC) is a Texas-based biotech company committed to the development and commercialization of its proprietary proteins and monoclonal antibodies for the treatment of infectious diseases, including HIV-1, Hepatitis (A, B, C), rabies, influenza A and B, tetanus and diphtheria. The Company’s multiple therapeutics also are being developed to treat Rheumatoid Arthritis and certain forms of cancer. Enzolytics technology for producing fully human monoclonal antibodies is now being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19, HIV-1 and the Feline Leukemia virus. Enzolytics has also identified conserved epitopes on and has plans to produce mAbs targeting many other viruses, including HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). Enzolytics has also analyzed epitopes of animal viruses and plans to produce mAbs for treating these animal viruses.
Enzolytics scientific team, Harry Zhabilov, Joseph Cotropia MD, and Gaurav Chandra MD, pioneered the Company’s proprietary therapeutics for treating infectious diseases as well as pioneering fully human monoclonal antibodies directed against many infectious diseases. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union, where it demonstrated beneficial outcomes. One antibody (designated as CLONE 3) has been demonstrated in tests in 5 international labs to fully neutralize over 95% of all strains and viral subtypes of HIV-1 against which it has been tested. Enzolytics currently has 2 labs, one at the Dallas Texas Metroplex and the other at Texas A&M University Institute for Preclinical Studies in College Station Texas. The Company also partners with Genscript Labs, the University of Strasbourg, France, California National Primate Research Center, Clinic Design, Danhson, and Samsung Biologics for recombinant Monoclonal Antibodies production.
Enzolytics reported preliminary results of Toxicology studies of the Company’s ITV-1 anti-HIV therapeutic confirming that the therapy is non-toxic. Establishing this result is essential to permitting under the European Medicines Agency (EMA) which will allow use of the therapeutic in the EU, followed by seeking FDA approval for use in North America. Enzolytics is anticipating entry into the markets of Rwanda, DR Congo, Botswana, and Kenya. Enzolytics’ Chief Science Officer, The WHO estimates a population of over 4,000,000 HIV infected individuals living with HIV in the four African countries where the Company will register the therapy. It is estimated that the hospitals will administer the treatment to 40,000 – 50,000 patients in the first year after the initial product production is completed. At this projected level of penetration (1% of the infected population), the expected gross revenue would exceed USD 45 Million in the first year.
$ENZC 💥MASSIVE PR💥
$250MM SPAC Deal with NASDAQ Ticker: SAGA closing on May 19th!
We did it 🏆
Spaces later today https://t.co/oSZrmV5FZT pic.twitter.com/1XTVyyneTW
— 𝐆𝐨𝐝𝐟𝐚𝐭𝐡𝐞𝐫 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 (@GodfatherCap) April 17, 2023
To Find out the inside Scoop on ENZC Subscribe to Newsytrends.com Right Now by entering your Email in the box below
Enzolytics IPF Immune™ (irreversible pepsin fraction) is a liquid nutritional supplement that acts an immune modulator to benefit the immune system by fortifying it against infections. The active components in the supplement have been registered with the FDA for use in the U.S. under NDI reg. no. 1083. The product is produced and sold by the Company pursuant to U.S. Patent No. 8,309,072. In tests, IPF Immune™ has demonstrated significant beneficial effects for various diseases, whether used alone or as a concomitant therapy, by bolstering the immune system. IPF has similar clinical benefits of Acyclovir (for treating Herpes) and Tamiflu (for treating Influenza) but those therapies were found to be 35 times more toxic to the body. The North American dietary supplements market size is large, valued at over $50 Billion in 2020, and expected to grow at a compound annual growth rate of 5.6% over each of the next 5 years.
ENZC has launched a significant campaign to market IPF Immune which will be offered on multiple e-commerce platforms including Amazon which accounts for almost 40% of the US online retail market. ENZC’s distributor is Nutritional Products International (NPI), a global brand management firm based in Florida, that has the reach and expertise to successfully position IPF Immune in the market. Also, NPIs sister Company; InHealth Media, specializing in marketing health, wellness, and sports nutrition products is overseeing a national TV tagging campaign along with a public relations and social media strategy targeted to build awareness.
The Chief Scientific Officer of VIRO, Harry Zhabilov, offered the following update on the production of ITV-1 vials for the Africa initiative and European Medicines Agency (“EMA”) permitting progress, “Production of the necessary anti-HIV immunotherapy treatments for use in the hospitals located in Central and Eastern regions of Africa was successfully completed on April 12, 2023, and will be delivered to the hospitals in the coming weeks.” With the preliminary results of Toxicology studies of the Company’s ITV-1 anti-HIV therapeutic confirming that the therapy is non-toxic and demonstrating the safety of administration of this patented proprietary immunotherapy, VIRO has negotiating a contract with a German company to perform the pharmacokinetics methodology the EMA has required as part of the EMA permitting process. VIRO wishes to recognize the contribution that Dr. Lachezar Ivanov has made in this endeavor.”
The CEO of BGEN, Dr. Gaurav Chandra, emphasized the progress being made by the Company using its Artificial Intelligence (AI) platform. “We continue to utilize our disruptive AI platform to identify conserved immutable epitopes on viruses and then produce species-specific monoclonal antibodies targeting those sites. We are advancing in production of multiple monoclonal antibodies against HIV, SARS-CoV-2, and the Feline Leukemia virus. Our AI platform drives the Company’s drug discovery and development and executes our strategy to produce multiple therapeutics protected by International Patents. We take pride in strengthening our IP portfolio and protecting the anti-virus therapeutics, their production method, use in diagnostics and prognostics. Our application of Artificial Intelligence to drug formulation and creation is a move ahead of big pharma’s monoclonal antibody discovery and development. We recognize that large pharmaceutical companies are now focused more than ever on the significant advantage provided by AI in creating highly successful therapeutics. We continue to engage with large pharma and discuss potential partnerships involving our AI platform.”
💥💥💥$2️⃣5️⃣0️⃣,0️⃣0️⃣0️⃣,0️⃣0️⃣0️⃣ #𝑺𝑷𝑨𝑪 𝑫𝒆𝒂𝒍 𝒘𝒊𝒕𝒉 #𝑵𝑨𝑺𝑫𝑨𝑸 𝑻𝒊𝒄𝒌𝒆𝒓 $𝑺𝑨𝑮𝑨 💥💥💥 #𝑳𝑬𝑻𝑺𝑮𝑶 #OTC #SpecialSituations #VIRO #BGEN #SAGA #Enzolytics #ITV1 #AI #HIV #SARSCoV2 #Felv #mAbs #Proprietary #Patents #Sagaliam #Biogenysis #Virogentics https://t.co/kVB724tjFd pic.twitter.com/d7jeTHry7c
— ✰𝓓𝓮𝓶𝓲𝓵𝔂𝓽𝓲𝓬𝓼✰ (@Demi6851) April 17, 2023
For More on ENZC Subscribe Right Now!
Currently trading at a $131 million market valuation ENZC os is 2,830,435,953. ENZC was one of the biggest runners of early 2021 skyrocketing to highs of $.90 after the merger with BioClonetics Immunotherapeutics. Currently the stock is still trading very close to its 52-week lows and has a significant gap to fill. ENZC recently hired accounting firm of Gries as the Company is planning to become a fully reporting 34 Act Filer with the SEC and uplist to OTCQB. ENZC is red hot and moving northbound with power after the Texas-based biotech announced it entered into a non-binding term sheet with SPAC Sagaliam Acquisition Corp. (NASDAQ: SAGA) for the sale of Biogenysis and Virogentics in a transaction valued at $250 million. The deal with be finalized by Mary 19, 2023. While Investors are still waiting for more details, in a spinoff such as this, investors will get shares in the new Company Sagaliam Acquisition Corp. (NASDAQ: SAGA) in addition to their shares in ENZC. As many ENZC investors have pointed out, after spinning off Biogenysis and Virogentics into SAGA the only things left will be Clone 3 and Covid MABs. Meanwhile ENZC shareholders will own shares in a Nasdaq listed biotech which raised $116.5 million in its initial public offering on December 23, 2021, and currently has $10 million in the treasury and expects to raise additional capital through a private investment in public equities (“PIPE”). We will be updating on ENZC when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in ENZC either long or short and we have not been compensated for this article.